AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02593981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 canisters of Placebo powder containing non-active ingredient to be mixed with water and ingested twice a day for 28 days
Study NCT03118739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad 9 mg+Febuxostat 80 mg
Description: Capsule administered orally, once daily for 24 weeks
Study NCT03118739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule administered orally, once daily for 24 weeks
Study NCT01054768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid and acetyl-L-carnitine
Description: none to report
Study NCT01054768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: none to report
Study NCT03959462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real anodal transcranial direct current stimulation
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used.
Study NCT03959462 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used.
Study NCT01232608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 months of exercise training
Study NCT02470546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1000mg twice a day
Study NCT02470546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1000mg twice a day
Study NCT03610087 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low Intensity Intervention
Description: Participants will have access via the online platform to the NAVIGATE self-help modules for physical activity, nutrition and quitting smoking with a list of community resources. Subjects will be sent a standard reminder emails once per week to complete their modules and connect with their main provider for any assistance.
Study NCT03610087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Intervention
Description: Participants will receive individualized treatment planning, in collaboration with a Care Coordinator, and the Virtual Care Team (VCT). Interactive modules on physical activity, nutrition and quitting smoking will be provided via the online platform. the virtual team will be engaged to provide treatment and/or recommendations regarding the following: increasing physical activity, improving nutrition and diet, smoking cessation (psychosocial support plus medications), and medication adherence. Participants in this arm will have weekly check-ins with their assigned Care Coordinator where they will be able to discuss VCT recommendations, and progress on their goals.
Study NCT01172769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: After dissolving and dilution 25 mg of temsirolimus will be administered i.v. once a week by 30 minute infusion.~Study treatment will continue until tumor progression or unless unacceptable toxicity is encountered.
Study NCT02908373 — intervention group
Intervention type: OTHER
Intervention: Implementation of the coaching model
Description: 20 hours methodological help for each nursing home and an implementation kit
Study NCT04511754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiential Psychotherapy Skill Training
Description: The Experiential Training intervention will include components of training not usually included in standard clinical training experiences; such components include opportunities for deliberate practice of the skills trained, live supervision and feedback, and discussion with a trainer focused on the skills taught and the trainees' performance.
Study NCT04511754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Psychotherapy Skill Training
Description: Standard didactic training with research support, examples, and opportunities to ask questions.
Study NCT03389542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Early mitral valve repair
Study NCT03389542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical interview and echocardiography
Description: Clinical interview and echocardiography every 6 months.
Study NCT00511875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline monohydrate
Description: 50mg once daily for 24 months
Study NCT00511875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo taken once daily for 24 months
Study NCT03475732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XueBiJing injection
Description: 100mL XueBiJing injection (dissolved with 100 mL of 0.9% normal saline),intravenous infusion for 1.25 h, q12h for 5 days
Study NCT00990080 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediacel® and Infanrix™-IPV/Hib
Description: 0.5 mL IM at 2,4 and 6 months of age
Study NCT02616887 — intervention group
Intervention type: RADIATION
Intervention: Single dose SBRT and VMAT technique
Description: One fraction of 18 Gy delivered in one day with VMAT and Flattening filter-free (FFF) beams.
Study NCT00784394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diindolylmethane
Description: Given PO
Study NCT00784394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT00784394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00784394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study NCT00784394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00784394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00784394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00784394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT03993548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 1 - Exercise
Description: Daily wellness element focusing on Exercise; adherence documented online daily
Study NCT03993548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 2 - Mindfulness
Description: Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
Study NCT03993548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 3 - Sleep Hygiene
Description: Daily wellness element focusing on sleep hygiene; adherence documented online daily
Study NCT03993548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 4 - Social Connectedness
Description: Daily wellness element focusing on Social Connectedness; adherence documented online daily
Study NCT03993548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 5 - Nutrition
Description: Daily wellness element focusing on Nutrition; adherence documented online daily
Study NCT03993548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 6 - Wellness Exercises
Description: Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
Study NCT03993548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 7 - Motivational Messages
Description: Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
Study NCT01723722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Concentration is 1mg/mL administered every 12 hours given on sliding scale in response to last NAS score.
Study NCT01723722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diluted Deodorized Tincture of Opium
Description: Concentration is 1:24 dilution for a concentration of 0.4%
Study NCT00033358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medroxyprogesterone
Description: Given intramuscularly
Study NCT00033358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol
Description: Given orally
Study NCT00033358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norgestrel
Description: Given orally
Study NCT00033358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02354664 — intervention group
Intervention type: OTHER
Intervention: Thoracic MRI
Description: Imaging of the diaphragm will be completed during resting breathing, and then during a maximal voluntary ventilation maneuver.
Study NCT02354664 — intervention group
Intervention type: OTHER
Intervention: Spirometry
Description: Upright forced vital capacity (FVC)
Study NCT02354664 — intervention group
Intervention type: OTHER
Intervention: Inspiratory Load Compensation
Description: A spring-loaded pressure device will resist inspiration. The patient must generate the threshold inspiratory pressure to receive airflow. The changes in breathing timing, flow and volume will be recorded.
Study NCT02354664 — intervention group
Intervention type: OTHER
Intervention: Maximal Inspiratory Pressure
Description: Measure the maximal airflow on inhalation
Study NCT02354664 — intervention group
Intervention type: OTHER
Intervention: Resting Breathing Pattern
Description: The breathing pattern will be assessed when the subject is seated and in a relaxed state.
Study NCT02354664 — intervention group
Intervention type: OTHER
Intervention: Respiratory Muscle Endurance Test
Description: Evaluates the time limit that a participant can maintain ventilation while breathing with a submaximal inspiratory threshold load.
Study NCT02078440 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bromocriptine mesylate
Description: Cycloset (bromocriptine mesylate quick release) 0.8 mg tablets, weight adjusted 1.6 mg- 4.8 mg
Study NCT04648540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 mic/kg/h
Description: In Group I (OFA) the following drugs will be administered preoperatively:~Acetaminophen 1 gm and Ketorolac 30 mg in 100 mL i.v. over 10 minutes Dexmedetomidine loading dose of 0.5 mic/kg i.v. over 10 minutes Lidocaine loading dose of 1.5 mg/kg i.v. over 10 minutes~The following drugs will be administered as a continuous infusion throughout the operation:~* Dexmedetomidine 0.5 mic/kg/h~* Lidocaine 0.5 mg/kg/h~The following drugs will be administered postoperatively:~Acetaminophen 1 gm/6h ketorolac 30 mg/8h Pregabalin 150 mg once at night Celecoxib 200 mg/24 hours
Study NCT00906347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 75 micrograms orally every 4 hours for up to 2 doses.
Study NCT00906347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital
Study NCT04354194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in sitting and supported with a pillow under the head, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the cervical region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
Study NCT04354194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manupilative Treatment
Description: Osteopathic Manupilative Treatment consist of stretching the fascia to the cervical region, soft tissue mobilization to the surrounding muscles, cervical manual traction, passive joint mobilization to the 7 cervical spine, passive joint mobilization to the 1st costa, passive joint mobilization to the clavicle and passive joint mobilization to the sternum mobilization in supine and prome positions.
Study NCT03618979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPP treatment
Description: The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of PPP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PPP. The physician will then repeat the procedure on the opposite side.
Study NCT03618979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP treatment
Description: The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PRP and remove the needle. The physician will then repeat the procedure on the opposite side and at the next level if indicated.
Study NCT03618979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP and PL Combo treatment
Description: The day prior to or the morning of the procedure patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP and 5 or 10 cc of PL and 2 or 4 cc of 14x PRP depending on if there will be one or two levels injected. Using sterile technique, under ultrasound visualization into the lumbar multifidus and onto the lamina, the physician will inject the PRP and remove the needle. Under intermittent x-ray, epidural flow is confirmed with contrast, the physician will inject 2cc of the PL and 1cc of 0.5% ropivacaine into the epidural space. Once flow is confirmed for the epidural injection and facet with contrast, 1cc of the 14x PRP is injected into the facet joint. Procedure repeated on the opposite side and next level if indicated.
Study NCT03917628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT630
Description: SCT630 single s.c. injection
Study NCT03917628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab-EU source
Description: adalimumab-EU source single s.c. injection
Study NCT02646345 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical checklist
Description: Use of the World Health Organization Surgical checklist
Study NCT02217722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ulcerative Colitis Diet
Description: we have postulated that a diet that increases butyrate through fiber exposure, reduces intestinal sulfur exposure, and increases vitamin D levels could be beneficial for patients with Ulcerative Colitis. To date, no study has explored this possibility.
Study NCT02217722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic cocktail
Description: We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
Study NCT02717221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-MPG
Description: N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-\[18F\] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)
Study NCT03113942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide 2 MG Oral Capsule [Pomalyst]
Description: Pomalidomide is an oral immunomodulatory derivative of thalidomide. Thalidomide and its derivatives are small molecules with broad effects on immune activation, including T-cell activation and responsiveness. Pomalidomide augments T cell responsiveness and proliferation by several mechanisms, many mediated by transcriptional regulation downstream of its primary target, cereblon. Effects include increased production of IL-2 and interferon-γ (IFN-γ), enhanced CD4+ and CD8+ T cell co-stimulation.
Study NCT03312387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic exercise performed 3/d per week during intervention
Study NCT03312387 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Aerobic exercise performed 3/d per week during intervention
Study NCT03312387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential Amino Acids
Description: Mixture of 10g of essential amino acids ingested throughout intervention
Study NCT03312387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10g of maltodextrin ingested throughout intervention
Study NCT04348383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: 6.25 mg/kg every 6 hours in 2 hours infusion for 7 or 15 days
Study NCT02123927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets
Study NCT04648540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl 1 mic/kg/hr
Description: In Group II (OA) patients will receive a continuous infusion of Fentanyl (1 mic/kg/h) Morphine 0.1 mg/kg PRN will be administered every 8 hours for postoperative analgesia
Study NCT03479697 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HIRREM
Description: Technology
Study NCT03479697 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIRREM
Description: Technology
Study NCT03479697 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Continued Current Care
Description: Continue their current clinical care.
Study NCT03479697 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continued Current Care
Description: Continue their current clinical care.
Study NCT04109274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise component: Aerobic exercise, using recumbent bikes, delivered within the cancer institution. Participants will take part in up to 30-minutes of moderate intensity (50-70% HRmax or 4-6/10 on Rate of Perceived Exertion scale)6 exercise for eight sessions during chemotherapy. An exercise specialist with experience in cancer rehabilitation will supervise the exercise component.
Study NCT04109274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management
Description: Eight SM modules will be delivered to participants. They will be viewed on an iPad prior to or after the exercise component. The goal of these modules is to aid participants in developing physical activity goals and action plans to continue with between sessions, with an overarching goal of helping them reach exercise guidelines for cancer survivors and the Canadian Physical Activity Guidelines
Study NCT04109274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster Sessions
Description: Four booster sessions will be provided to participants in this group. These will occur at 2, 4, 6, and 8 months post intervention completion. An assessor trained in behavioural counselling will provide booster sessions by phone and will discuss the individuals physical and emotional condition, current exercise level, accomplishment of previously set goals and action plans, and perceived barriers to participation in exercise. The assessor will use facilitation strategies to aid participants in devising strategies to overcome barriers and set realistic goals and action plans.
Study NCT06253364 — intervention group
Intervention type: DRUG
Intervention: PD-1 monoclonal antibody and lenvatinib
Description: Adjuvant PD-1 group: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.~Adjuvant PD-1 plus Lenvatinib group: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200 mg IV 21 days for 9 cycles; lenvatinib is initiated orally 2-4 weeks postoperatively for 6 months.
Study NCT02123927 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-438 placebo-matching tablets
Study NCT02857881 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: De-epithelization and therapeutic photokeratectomy
Study NCT02020603 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine injection plus soft coagulation using hemostatic forceps
Study NCT02020603 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine injection plus argon plasma coagulation
Study NCT03922477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered to participants by IV infusion at a fixed dose starting on Day 22 of Cycle 1. In subsequent cycles (Cycles 2 and beyond), IV atezolizumab will be given every 2 weeks (Q2W) on Days 8 and 22 of each 28-day cycle.
Study NCT03922477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hu5F9-G4
Description: Two priming doses of 1 mg/kg of Hu5F9-G4 will be administered to participants by continuous IV infusion on Days 1 and 4 of Cycle 1, followed by loading doses of 15 mg/kg IV on Day 8 and 30 mg/kg IV on Day 11. Starting on Day 15 of Cycle 1, Hu5F9-G4 maintenance will be given by IV infusion at a dose of 30 mg/kg once a week (QW) of each 28-day cycle. Dosing for de-escalation, if needed: Hu5F9-G4 will be given as two priming doses of 1 mg/kg IV on Days 1 and 4, followed by loading doses of 10 mg/kg IV on Day 8 and 15 mg/kg on Day 11. Starting on Day 15, maintenance treatment with Hu5F9-G4 will be given by IV infusion at a dose of 15 mg/kg once a week (QW).